The Allosteric Edge: Quantum Logic Design of a GSK-3$\beta$ Allosteric Modulator (UmbraKinase-42) and Second-Generation IP Disclosure

The clinical development of Glycogen Synthase Kinase 3 Beta ($\text{GSK-3}\beta$) inhibitors for Alzheimer's Disease ($\text{AD}$) has been predominantly focused on $\text{ATP}$-competitive mechanisms. To bypass this critical limitation, we present a second-generation intellectual property asset, UmbraKinase-42. Utilizing our in silico Agency system—which leverages Recursive Resonance Modeling ($\text{RRM}$) to identify novel druggable pockets—we designed $\text{UmbraKinase-42}$ as a highly selective, non-$\text{ATP}$-competitive allosteric modulator. This molecule is computationally optimized to bind a unique allosteric pocket identified via Quantum Logic blind docking simulations. Umbra's predictions indicate an exceptional selectivity profile ($\text{target} > 100\text{-fold}$) and a distinct pharmacokinetic profile ($\text{target K}_\text{d}